195 related articles for article (PubMed ID: 35832429)
1. Minimizing Mitogenic Potency of Insulin Analogues Through Modification of a Disulfide Bond.
Ong SC; Belgi A; Merriman AL; Delaine CA; van Lierop B; Andrikopoulos S; Robinson AJ; Forbes BE
Front Endocrinol (Lausanne); 2022; 13():907864. PubMed ID: 35832429
[TBL] [Abstract][Full Text] [Related]
2. Probing the correlation between insulin activity and structural stability through introduction of the rigid A6-A11 bond.
Ong SC; Belgi A; van Lierop B; Delaine C; Andrikopoulos S; MacRaild CA; Norton RS; Haworth NL; Robinson AJ; Forbes BE
J Biol Chem; 2018 Jul; 293(30):11928-11943. PubMed ID: 29899115
[TBL] [Abstract][Full Text] [Related]
3. Insulin in motion: The A6-A11 disulfide bond allosterically modulates structural transitions required for insulin activity.
van Lierop B; Ong SC; Belgi A; Delaine C; Andrikopoulos S; Haworth NL; Menting JG; Lawrence MC; Robinson AJ; Forbes BE
Sci Rep; 2017 Dec; 7(1):17239. PubMed ID: 29222417
[TBL] [Abstract][Full Text] [Related]
4. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency.
Hansen BF; Danielsen GM; Drejer K; Sørensen AR; Wiberg FC; Klein HH; Lundemose AG
Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):271-9. PubMed ID: 8670118
[TBL] [Abstract][Full Text] [Related]
5. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.
Eckardt K; May C; Koenen M; Eckel J
Diabetologia; 2007 Dec; 50(12):2534-43. PubMed ID: 17898992
[TBL] [Abstract][Full Text] [Related]
6. Mitogenic potency of insulin glargine.
Zełobowska K; Gumprecht J; Grzeszczak W
Endokrynol Pol; 2009; 60(1):34-9. PubMed ID: 19224503
[TBL] [Abstract][Full Text] [Related]
7. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
8. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities.
Ciaraldi TP; Sasaoka T
Horm Metab Res; 2011 Jan; 43(1):1-10. PubMed ID: 20938889
[TBL] [Abstract][Full Text] [Related]
9. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
Kurtzhals P; Schäffer L; Sørensen A; Kristensen C; Jonassen I; Schmid C; Trüb T
Diabetes; 2000 Jun; 49(6):999-1005. PubMed ID: 10866053
[TBL] [Abstract][Full Text] [Related]
10. The metabolic and mitogenic properties of basal insulin analogues.
Tennagels N; Werner U
Arch Physiol Biochem; 2013 Feb; 119(1):1-14. PubMed ID: 23373726
[TBL] [Abstract][Full Text] [Related]
11. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
12. Insulin and its analogues and their affinities for the IGF1 receptor.
Varewijck AJ; Janssen JA
Endocr Relat Cancer; 2012 Oct; 19(5):F63-75. PubMed ID: 22420005
[TBL] [Abstract][Full Text] [Related]
13. Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties.
Kellerer M; Häring HU
Exp Clin Endocrinol Diabetes; 2001; 109(1):63-4. PubMed ID: 11573144
[No Abstract] [Full Text] [Related]
14. Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells.
ter Braak B; Wink S; Koedoot E; Pont C; Siezen C; van der Laan JW; van de Water B
Breast Cancer Res; 2015 Jul; 17(1):97. PubMed ID: 26187749
[TBL] [Abstract][Full Text] [Related]
15. The differential effects of pp120 (Ceacam 1) on the mitogenic action of insulin and insulin-like growth factor 1 are regulated by the nonconserved tyrosine 1316 in the insulin receptor.
Soni P; Lakkis M; Poy MN; Fernström MA; Najjar SM
Mol Cell Biol; 2000 Jun; 20(11):3896-905. PubMed ID: 10805733
[TBL] [Abstract][Full Text] [Related]
16. Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogues.
Glendorf T; Knudsen L; Stidsen CE; Hansen BF; Hegelund AC; Sørensen AR; Nishimura E; Kjeldsen T
PLoS One; 2012; 7(2):e29198. PubMed ID: 22383948
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
Sommerfeld MR; Müller G; Tschank G; Seipke G; Habermann P; Kurrle R; Tennagels N
PLoS One; 2010 Mar; 5(3):e9540. PubMed ID: 20209060
[TBL] [Abstract][Full Text] [Related]
18. Surface-expressed insulin receptors as well as IGF-I receptors both contribute to the mitogenic effects of human insulin and its analogues.
Lundby A; Bolvig P; Hegelund AC; Hansen BF; Worm J; Lützen A; Billestrup N; Bonnesen C; Oleksiewicz MB
J Appl Toxicol; 2015 Jul; 35(7):842-50. PubMed ID: 25413577
[TBL] [Abstract][Full Text] [Related]
19. Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding.
Shymko RM; Dumont E; De Meyts P; Dumont JE
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):675-83. PubMed ID: 10215607
[TBL] [Abstract][Full Text] [Related]
20. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor.
Ish-Shalom D; Christoffersen CT; Vorwerk P; Sacerdoti-Sierra N; Shymko RM; Naor D; De Meyts P
Diabetologia; 1997 Jul; 40 Suppl 2():S25-31. PubMed ID: 9248698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
